Jon Aning

ELISPE says a HUGE thank you to our top recruiting sites! @Krish_Narahari, @jonathananing, @Heer_Lab, @vishhanchanale, @benchallacombe, @BURSTurology, @NorthBristolNHS, @UHSFT, @uclh, @GSTTnhs, @SwanseabayNHS, @nhsUHLG

ELIPSE has reached 50% of recruitment target - 540 participants! Thanks to everyone who has helped us reach this momentous milestone! @Krish_Narahari, @jonathananing, @Heer_Lab, @vishhanchanale, @benchallacombe, @BURSTurology

Immunotherapy Escalation in BCG-Naïve NMIBC: Time for Selectivity, Not Enthusiasm euoncology.europeanurology.com/article/S2588-… The ALBAN, CREST, and POTOMAC phase 3 trials in BCG-naïve high-risk NMIBC highlight both promise and limitations of adding checkpoint inhibitors to BCG. While optimized BCG alone achieves over 70% three-year event-free survival, PD-1 combinations modestly reduce recurrences but increase toxicity. No survival or progression benefit is yet shown, raising concerns about overtreatment and cost. Future efforts must prioritize patient selection, progression endpoints, and molecular risk stratification currently in practice. #BladderCancer @UroMoschini Maria Carmen Mir @jonathananing Alessandro Volpe @PiedmontHealth @OncoAlert 🚨

Geoff Twentyman, Lee Mansell & expert urologist Professor Jonathan Aning were among the panelists at our Prostate Cancer Awareness Evening at The Mem 💬 A fantastic and informative evening in aid of The John Green Campaign 💙 @BristolRoversCT | @NorthBristolNHS | @uhbwNHS

Interested in learning more about our work on variation in contemporary female radical cystectomy care across the UK & Ireland after hearing @LizzyDay3’s presentation at #EAU26? Check out our @urotoday “Beyond the Abstract” where we dive deeper 👇🏽 🔗 in comments

🔗 urotoday.com/recent-abstrac… @jonathananing @FP_Bizzarri @aw_nelson @AlexandraColqu2

Join us on Wednesday 25 March at 6:30pm for a Prostate Cancer Awareness Evening at the Mem. Geoff Twentyman will be hosting a discussion on symptoms, early detection, rehabilitation and recovery, with a panel of medical experts and our campaign ambassador John Green.

Published today - "AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study" pubmed.ncbi.nlm.nih.gov/41718862/

A fantastic and inspirational evening last night as the team attended and spoke at the Annual Prostate Cancer Educational Evening along side @jonathananing @AKoupparis Prof Hashim Hashim and many others! @rjcousins4 @MartaCobos1984 @bui_nbt @ResearchNBT #ProstateCancer 💙

🚨Female radical cystectomy practice in the UK and Ireland is highly variable- from what we counsel, to the organs we preserve & how we provide survivorship care New data from our survey @BJUIjournal 👇🏽👇🏽👇🏽 🔗 doi.org/10.1111/bju.70…

Huge thanks to Helena Burden and John McGrath for the invitation to the Bristol Urological Institute mtg ✅Transformational, inspiring work being led by the 🤩 team in South West England & other colleagues in @NHSEngland ✅ Immaculate vibes in the unit ✅beautiful city ❤️🙏

Fascinating to hear from @niyatilobo during @BAUSurology #URUK meeting talk about #NMIBC metastasis in #BladderCancer •Not as rare as we thought •under-studied •unknown clonal composition •poss window to differentiate lethal vs indolent Ta/1 disease @jonathananing @LizzyDay3

Out on The Guardian A new £1.9 million UK study, the Vanguard Path trial, will evaluate the ArteraAI Prostate Biopsy Assay—an artificial intelligence tool designed to aid prostate cancer diagnosis and treatment decisions—across NHS hospitals. Led by the University of Oxford and funded by Prostate Cancer UK, the three-year study will analyze biopsies from over 4,000 men to determine how effectively the AI model, which generates personalized risk scores from digitized biopsy images, predicts treatment benefit. The tool has already demonstrated value in U.S. trials by identifying which men with high-risk prostate cancer benefit from abiraterone and helping guide hormone and radiotherapy use in less aggressive disease. The UK trial will first validate its predictive accuracy using retrospective patient data, then prospectively test its real-world impact at NHS sites in Oxford, Bristol, and Glasgow. Researchers aim to assess whether the tool influences clinicians’ treatment recommendations, shortens decision-making time, and ultimately reduces both under- and overtreatment, paving the way for potential NHS adoption if proven accurate, cost-effective, and clinically beneficial. #ProstateCancer theguardian.com/society/2025/n… @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur

Will we cross paths in your city soon? Together with national societies, the EAU will share vital updates shaping the field. Check out where we're off too next this month 👉uroweb.org/news/where-are…

Congratulations @jonathananing co-leading a study with his team @bui_nbt using a new AI tool to improve #prostatecancer diagnosis. The VANGUARD PATH study could open the door to personalised prostate cancer care. ow.ly/Uk3n50XlHEv @NorthBristolNHS

Hear directly from the experts about the KEYNOTE, SunRISe-4, and NIAGARA trials as they discuss the latest data from ESMO 2025 in this new UROwebinar. Register now and claim your CME credit! 👇#1982" target="_blank" rel="nofollow noopener">webinars.uroweb.org/EAU/webinars/#… @jonathananing @Prof_Nick_James @BenjaminPradere

As part of our FRCS (Urol) Revision Course 2025 in #Cambridge @HelenaBurden reflects on a successful event seeing our Trainees developing themselves into the next-generation of urological surgeons with a variety of lectures and Viva interviews taken place over the past four days.

Great news from North Bristol #elipse. @Krish_Narahari @jonathananing @Heer_Lab @vishhanchanale @benchallacombe @BURSTurology @AKoupparis

@Krish_Narahari @jonathananing @Heer_Lab @vishhanchanale @benchallacombe @BURSTurology

just over 6w to go until #ERUS25! we need to smash 🇬🇧 registration record 💪🏽 book your study leave today! register for Europe’s premier robotic urology meeting erus25.org we can’t wait to host you all in London 😎